Andrea Calcagno1, Luigi Celani1, Mattia Trunfio1, Giancarlo Orofino1, Daniele Imperiale1, Cristiana Atzori1, Vincenzo Arena1, Gabriella d'Ettorre1, Giovanni Guaraldi1, Magnus Gisslen1, Giovanni Di Perri1. 1. Unit of Infectious Diseases (C. Andrea, MT, GDP), Department of Medical Sciences, University of Torino, Italy; Department of Public Health and Infectious Diseases (LC, GE), Sapienza University of Rome, Italy; "Divisione A" Unit of Infectious Diseases (GO), Ospedale Amedeo di Savoia, ASL Città di Torino, Italy; Unit of Neurology (DI, C. Atzori), Ospedale Maria Vittoria, ASL Città di Torino, Italy; AFFIDEA Irmet PET/CT Center (VA), Torino, Italy; Department of Surgical (GG), Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy; Department of Infectious Diseases (MG), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden; and Region Västra Götaland (MG), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden.
Abstract
OBJECTIVE: Given the aging of people living with HIV (PLWH) and the high prevalence of HIV-associated neurocognitive disorders, we aimed at describing the clinical, instrumental, and CSF features of PLWH diagnosed with Alzheimer dementia (AD). METHODS: The databases of 3 large Italian outpatient clinics taking care of more than 9,000 PLWH were searched for the diagnosis of AD. After obtaining patients' or their next of kin's consent for publication, anonymous data were collected in an excel spreadsheet and described. Routinely collected CSF biomarkers and radiologic imaging results were recorded whether available. RESULTS: Four patients were included in this case series who were diagnosed with AD aged between 60 and 74 years. All participants were on highly active antiretroviral therapy and showed nondetectable serum HIV RNA. Memory impairment was the most prominent cognitive feature. The diagnosis was obtained considering the exclusion of other potential causes, MRI and fluorodeoxyglucose-PET features, and, in (in 2/4), CSF AD biomarkers levels. In 1 patient, longitudinal CSF tau/p-tau increased, and beta-amyloid1-42 decreased over time despite antiretroviral therapy containing nucleotide reverse transcriptase inhibitors. CONCLUSIONS: In older PLWH cognitive symptoms may represent the onset of AD: a multidisciplinary team may be needed for reaching a likely in vivo diagnosis.
OBJECTIVE: Given the aging of people living with HIV (PLWH) and the high prevalence of HIV-associated neurocognitive disorders, we aimed at describing the clinical, instrumental, and CSF features of PLWH diagnosed with Alzheimer dementia (AD). METHODS: The databases of 3 large Italian outpatient clinics taking care of more than 9,000 PLWH were searched for the diagnosis of AD. After obtaining patients' or their next of kin's consent for publication, anonymous data were collected in an excel spreadsheet and described. Routinely collected CSF biomarkers and radiologic imaging results were recorded whether available. RESULTS: Four patients were included in this case series who were diagnosed with AD aged between 60 and 74 years. All participants were on highly active antiretroviral therapy and showed nondetectable serum HIV RNA. Memory impairment was the most prominent cognitive feature. The diagnosis was obtained considering the exclusion of other potential causes, MRI and fluorodeoxyglucose-PET features, and, in (in 2/4), CSF AD biomarkers levels. In 1 patient, longitudinal CSF tau/p-tau increased, and beta-amyloid1-42 decreased over time despite antiretroviral therapy containing nucleotide reverse transcriptase inhibitors. CONCLUSIONS: In older PLWH cognitive symptoms may represent the onset of AD: a multidisciplinary team may be needed for reaching a likely in vivo diagnosis.
Authors: Jerel Adam Fields; Brian Spencer; Mary Swinton; Emma Martine Qvale; María J Marquine; Arina Alexeeva; Sarah Gough; Benchawanna Soontornniyomkij; Elvira Valera; Eliezer Masliah; Cristian L Achim; Paula Desplats Journal: J Neurochem Date: 2018-11-26 Impact factor: 5.372
Authors: A Calcagno; C Atzori; A Romito; D Vai; S Audagnotto; M L Stella; C Montrucchio; D Imperiale; G Di Perri; S Bonora Journal: J Neurovirol Date: 2015-08-06 Impact factor: 2.643
Authors: Deepak Kumar Vijaya Kumar; Se Hoon Choi; Kevin J Washicosky; William A Eimer; Stephanie Tucker; Jessica Ghofrani; Aaron Lefkowitz; Gawain McColl; Lee E Goldstein; Rudolph E Tanzi; Robert D Moir Journal: Sci Transl Med Date: 2016-05-25 Impact factor: 17.956
Authors: Brian Giunta; Jared Ehrhart; Demian F Obregon; Lucy Lam; Lisa Le; JingJi Jin; Francisco Fernandez; Jun Tan; R Douglas Shytle Journal: Mol Brain Date: 2011-06-07 Impact factor: 4.041
Authors: Lachlan R Gray; Gilda Tachedjian; Anne M Ellett; Michael J Roche; Wan-Jung Cheng; Gilles J Guillemin; Bruce J Brew; Stuart G Turville; Steve L Wesselingh; Paul R Gorry; Melissa J Churchill Journal: PLoS One Date: 2013-04-16 Impact factor: 3.240
Authors: Adonis Sfera; Karina G Thomas; Christina V Andronescu; Nyla Jafri; Dan O Sfera; Sarvin Sasannia; Carlos M Zapata-Martín Del Campo; Jose C Maldonado Journal: Front Neurosci Date: 2022-05-12 Impact factor: 5.152
Authors: Mattia Trunfio; Cristiana Atzori; Marta Pasquero; Alessandro Di Stefano; Daniela Vai; Marco Nigra; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno Journal: Viruses Date: 2022-04-04 Impact factor: 5.818